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Abstract
Background: Resveratrol have been known to possess many pharmacological properties including antioxidant,
cardioprotective and anticancer effects. Although current studies indicate that resveratrol produces neuroprotection
against neurological disorders, the precise mechanisms for its beneficial effects are still not fully understood. We investigate
the effect of anti-inflammatory and mechamisms of resveratrol by using lipopolysaccharide (LPS)-stimulated murine
microglial BV-2 cells.
Methodology/Principal Findings: BV-2 cells were treated with resveratrol (25, 50, and 100 mM) and/or LPS (1 mg/ml). Nitric
oxide (NO) and prostaglandin E2 (PGE2) were measured by Griess reagent and ELISA. The mRNA and protein levels of
proinflammatory proteins and cytokines were analysed by RT-PCR and double immunofluorescence labeling, respectively.
Phosphorylation levels of PTEN (phosphatase and tensin homolog deleted on chromosome 10), Akt, mammalian target of
rapamycin (mTOR), mitogen-activated protein kinases (MAPKs) cascades, inhibitor kB-a (IkB-a) and cyclic AMP-responsive
element-binding protein (CREB) were measured by western blot. Resveratrol significantly attenuated the LPS-induced
expression of NO, PGE2, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-a (TNF-a),
interleukin-1b (IL-1b) and nuclear factor-kB (NF-kB) in BV-2 cells. Resveratrol increased PTEN, Akt and mTOR phosphorylation
in a dose-dependent manner or a time-dependent manner. Rapamycin (10 nM), a specific mTOR inhibitor, blocked the
effects of resveratrol on LPS-induced microglial activation. In addition, mTOR inhibition partially abolished the inhibitory
effect of resveratrol on the phosphorylation of IkB-a, CREB, extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-
terminal protein kinase (JNK), and p38 mitogen-activated protein kinase (p38 MAPK).
Conclusion and Implications: This study indicates that resveratrol inhibited LPS-induced proinflammatory enzymes and
proinflammatory cytokines via down-regulation phosphorylation of NF-kB, CREB and MAPKs family in a mTOR-dependent
manner. These findings reveal, in part, the molecular basis underlying the anti-inflammatory properties of resveratrol.
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Introduction
Microglia, the resident immune cells in the brain, serves the first
line of defense when injury or disease occurs and play a homeostatic
role in the central nervous system (CNS) [1]. Although activated
microglia scavenge dead cells from the CNS and secrete different
neurotrophic factors for neuronal survival [2,3], it is believed that
severe activation causes various autoimmune responses leading to
neuronal death and brain injury [4,5]. Activation of microglia and
consequent release of proinflammatory and/or cytotoxic factors
such as tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b),
nitric oxide (NO), prostaglandin E2 (PGE2), reactive oxygen species
(ROS), inducible nitric oxide synthase (iNOS), and cyclooxygenase-
2 (COX-2) are believed to contribute to neuronal damage,
particularly in neurodegenerative diseases [6,7,8,9]. Subsequently,
the damaged neurons release toxic soluble factors, which in
turn induce microglial activation termed as reactive microgliosis
[10].
It has recently been suggested that the activation of microglia
can increase neurotoxicity through the production of proinflam-
matory and cytotoxic factors in neuron-glia cultures treated with
lipopolysaccharide (LPS), b-amyloid, glutamate, and arachidonate
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32195[11]. One of these widely used stimuli is LPS, a bacterial
endotoxin used to study experimentally induced infection,
inflammation, or tissue damage, as well as the biochemistry of
inflammatory responses. LPS activates nuclear factor-kB (NF-kB),
cyclic AMP responsive element-binding protein (CREB) and
mitogen-activated protein kinases (MAPKs) family, which are
classified into at least three components: extracellular signal-
regulated kinases 1/2 (ERK 1/2), c-Jun N-terminal kinase (JNK),
and p38 MAPK [12] and which have been implicated in the
release of immune-related cytotoxic factors such as iNOS, COX-2,
and proinflammatory cytokines [7,12].
The mammalian target of rapamycin (mTOR) is a serin/
threonin protein kinase with a central role in the regulation of cell
growth and proliferation, as well as of physiological processes such
as transcription, mRNA turnover and translation, ribosomal
biogenesis, vesicular trafficking, autophagy and cytoskeletal
organization [13]. mTOR exists in two functionally distinct
complexes called mTORC1 and mTORC2. mTORC1, com-
posed of mTOR, mLST8/GbL (G protein b-subunit like protein)
and raptor (regulatory associated protein of mTOR) is sensitive to
rapamycin, unlike mTORC2 which is composed of mTOR,
mLST8/GbL and rictor [14]. In freshly isolated human
monocytes and primary myeloid dendritic cells (DCs), mTOR
activation inhibits the production of proinflammatory cytokines
while it enhances the release of the anti-inflammatory cytokine by
blocking NF-kB activation and increasing STAT3 activity [15].
Thus, the mTOR pathway might have opposite roles in the
immune system [16]. Recent studies indicated that mTOR
selectively controls microglial activation in response to proin-
flammatory cytokines and appears to play a crucial role in
microglial viability [17], mediates iNOS induction during hypoxia
in the BV-2 microglial cell line [18], and reduces microglia/
macrophages activation and increases the number of surviving
neurons after brain injury [19], suggesting a key role in the control
of microglial functions.
Resveratrol (3, 4, 5-trihydroxy-trans-stilbene) is a natural non-
flavonoid polyphenolic found in grapes, red wine, mulberries,
knotweed, peanuts and other plants (Figure 1) [20]. Although these
plants and their extracts have been used for various therapeutic
purposes by ancient cultures, resveratrol itself was first described in
1940 as a phenolic component of the medicinal herb hellebore
[21]. There are numerous reports in the literature show that
resveratrol dampens inflammation in arthritis and immune res-
ponsiveness in autoimmune diseases [22,23], suppresses angio-
genesis and metastasis in several cancers [24], and inhibits ROS
products and platelet aggregation in cardiovascular diseases
[25,26]. Resveratrol can penetrate the blood-brain barrier to
exert strong neuroprotective effects in vivo [21]. In addition to
these beneficial actions, resveratrol has been noted for its anti-
inflammatory activities. It can attenuate the activation of immune
cells and the subsequent synthesis and release of proinflammatory
mediators through the inhibition of the transcriptional factors such
as NF-kB and activator protein-1 (AP-1) [27]. Although current
studies indicate that resveratrol produces neuroprotection against
neurological disorders, such as Alzheimer disease, Parkinson
disease, and Huntington disease [28], the precise mechanisms
for its beneficial effects are still not fully understood.
This study examined the effects of resveratrol on LPS-
stimulated inflammatory responses in microglia and the potential
role of mTOR in this process. To this end, a fuller understanding
of the molecular mechanism of microglial activation is clearly
desirable in delineating the therapeutic target molecules to reduce
the brain inflammation and resulting neuronal injury or death in
neurodegenerative diseases.
Results
Resveratrol and/or rapamycin do not affect the viability
of BV-2 cells
The cytotoxicity of resveratrol and rapamycin was evaluated in
the presence or absence of LPS by MTT assay. Resveratrol and/
or rapamycin did not decrease the viability of the BV-2 microglial
cells when they were incubated with or without LPS (1 mg/ml) in
the presence or absence of resveratrol (25, 50, and 100 mM) and/
or rapamycin (10 nM) for 18 h. Hence, resveratrol and/or
rapamycin exerted no significant cytotoxicity on BV-2 microglial
cells (Figure 2).
Resveratrol activates the mTOR signaling pathway in
BV-2 cells
To identify the signaling pathways that are activated by
resveratrol in cultured microglial BV-2 cells. We investigated
whether resveratrol could activate the mTOR signaling pathway
and affect LPS-induced mTOR phosphorylation. Incubation of
BV-2 cells with resveratrol (50 mM) significantly induced phos-
phorylation of serine residue 2881 of mTOR in time-dependent
manner (Figure 3A). Furthermore, when the cells were treated
with resveratrol (50 mM) for 1 h before LPS (1 mg/ml) stimulation,
mTOR phosphorylation was elevated initially and further in-
creased steadily during the 1 h incubation with LPS. The levels of
phospho-mTOR were always significantly higher in the cells
pretreated with resveratrol compared with the cells treated with
LPS only (Figure 3B).
PTEN (phosphatase tensin homolog on chromosome 10) and
Akt is an effective modulator of mTOR, so we further examined
whether resveratrol affects PTEN and Akt phosphorylation
induced by LPS. When the cells were treated with resveratrol
(25, 50, and 100 mM) for 1 h before LPS (1 mg/ml) stimulation for
40 min, resveratrol significantly increased phosphorylation of
PTEN, so it downregulated PTEN activity by its phosphorylation
(Figure 3C), and the level of phospho-Akt was always significantly
higher in dose-dependent manner in the cells pretreated with
resveratrol compared with the cells treated with LPS only
(Figure 3D).
mTOR is involved in resveratrol-inhibited releases of NO
and PGE2 induced by LPS in BV-2 cells
Treatment of BV-2 cells with LPS (1 mg/ml) caused a
significantly increase in NO and PGE2 releases in comparison
with untreated controls by Griess reagent and enzyme-linked
immunosorbent assay (ELISA), after 8 h exposure to LPS.
Resveratrol (25, 50, and 100 mM) inhibited the LPS-induced
production of NO and PGE2 over the concentration range used
here. However, following the pretreatment of cells with 10 nM
Figure 1. Chemical structure of resveratrol.
doi:10.1371/journal.pone.0032195.g001
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reversed resveratrol-downregulated levels of NO and PGE2
induced by LPS (Figures 4A and B).
mTOR is required for resveratrol-inhibited expression of
iNOS and COX-2 proteins and mRNA induced by LPS in
BV-2 cells
To investigate the effect of resveratrol on iNOS and COX-2, the
expression of both proinflammatory enzymes was examined by
double immunofluorescence labeling and RT-PCR assay. BV-2
cells were stimulated with LPS (1 mg/ml) for 4 h which resulted in
increase of the proteinand mRNA levels of iNOS and COX-2. Pre-
treatment with resveratrol (25, 50, and 100 mM) inhibited iNOS
and COX-2 protein and mRNA levels significantly (Figures 5 and
6), compared with LPS-treated cells. However, following the
pretreatment of cells with 10 nM rapamycin (1 h before),
resveratrol could not inhibit upregulation of the protein and mRNA
levels of iNOS and COX-2 induced by LPS (Figures 5 and 6).
mTOR is involved in resveratrol-attenuated expression of
the proinflammatory cytokines TNF-a and IL-1b in LPS
stimulated BV-2 cells
To investigate whether resveratrol represses the production of
TNF-a and IL-1b and whether mTOR is involved in this process in
BV-2 cells, cells were stimulated with LPS (1 mg/ml) for 4 h in the
presence or absence of resveratrol (25, 50, and 100 mM). After
treatment with LPS, the protein levels of the cytokines in BV-2
cells were evaluated by immunofluorescence labeling which
showed that TNF-a as well as IL-1b immunoexpression was
noticeably enhanced by LPS stimulation. Pretreatment with
resveratrol resulted in a drastic decrease in cytokine expression.
However, in BV-2 cells subjected to pretreatment with 10 nM
rapamycin (1 h before), TNF-a and IL-1b immunofluorescence
intensity was obviously increased (Figures 7A and 8A).
To further investigate whether the inhibitory effect of
resveratrol on TNF-a and IL-1b production is due to the reduced
expression of cognate genes, the effect of resveratrol on mRNA
expression of TNF-a and IL-1b was assessed in LPS-stimulated
BV-2 cells. As shown in Figures 7B and 8B, the mRNA expression
of these inflammatory mediators was very low or hardly detectable
in unstimulated BV-2 cells. However, BV-2 cells expressed high
levels of TNF-a and IL-1b mRNA when stimulated with LPS
(1 mg/ml; 4 h). More importantly, resveratrol suppressed LPS-
induced expression of these genes. In parallel to the double
immunofluorescence labeling, pretreatment of BV-2 cells with
rapamycin significantly reversed resveratrol-downregulated levels
of TNF-a and IL-1b mRNA (Figures 7B and 8B).
mTOR pathway is linked to resveratrol-suppressed
LPS-induced expression of NF-kB/RelA protein,
phosphorylation of IkB-a and CREB, and protects against
LPS-induced activation in BV-2 cells
To further elucidate the mechanisms of resveratrol on the
inhibition of expression of iNOS, COX-2, and proinflammatory
cytokines in microglia, we next examined the effect of resveratrol
on NF-kB and CREB, the two major transcription factors involved
in the expression of these inflammatory mediators. NF-kB
activation includes IkB-a’s degradation through phosphorylation
and a subsequent nuclear NF-kB translocation. We determined
whether the resveratrol inhibitory effect was through the blockade
of NF-kB activation in BV-2 cells. As shown in Figure 9, pre-
treatment of resveratrol (25, 50, and 100 mM) significantly
suppressed the LPS (1 mg/ml; 4 h) induced expression levels of
NF-kB/RelA mRNA and protein, as well as phosphorylation of
IkB-a in a mTOR-dependent manner (Figure 10A).
CREB is the physiological substrate for MAPKs and stress-
activated protein kinases-1 (MSK1), which is activated by ERK
and p38 MAPK-mediated signaling in response to LPS. We next
determined whether resveratrol regulates the phosphorylation of
CREB and whether such an effect, if any, is mediated through the
mTOR signaling pathway in BV-2 cells. As demonstrated in
Figure 10B, CREB activation was markedly stimulated by LPS;
additionally the activation was significantly inhibited by treatment
with resveratrol at 50 and 100 mM; nonetheless, pre-treatment
Figure 2. Effects of resveratrol on the cell viability of BV-2 microglial cells. BV-2 cells were treated with 25, 50, and 100 mM of resveratrol
without LPS treatments or with 1 mg/ml LPS or with 10 nM rapamycin treatments for 18 h. BV-2 cells viabilities were measured and expressed as
mean 6 SEM for three independent experiments.
doi:10.1371/journal.pone.0032195.g002
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CREB most drastically.
Inhibition of MAPKs signaling by resveratrol is mTOR-
dependent during BV-2 cells activation by LPS
The effect of resveratrol on MAPKs, which are upstream
signaling molecules in inflammatory reactions, was examined in
LPS-stimulated BV-2 cells. Western blot analysis was carried out
using the phospho- or total forms of antibodies against the
three MAPKs, including ERK1/2, JNK, and p38 MAPK. It
was observed that resveratrol at different concentrations 25,
50, and 100 mM significantly decreased the LPS-stimulated
phosphorylation of ERK1/2 at 30 min, respectively, whereas it
had no effect on the expression level of ERK1/2 in LPS-
stimulated BV-2 cells (Figure 10C). Likewise, resveratrol at all
concentrations significantly suppressed the phosphorylation of
JNK and p38 MAPK, respectively, but did not affect the
expression levels of JNK and p38 MAPK in LPS-stimulated BV-
2 cells (Figures 10D and E). To determine the upstream regulators
of MAPKs signaling in resveratrol-inhibited activation of BV-2
cells by LPS, BV-2 cells were pretreated with 10 nM rapamycin
(1 h before) and, very interestingly, this reversed the effect of
resveratrol-inhibited phosphorylation of ERK1/2, JNK and p38
MAPK (Figures 10C, D and E).
Figure 3. Resveratrol activates the Akt/mTOR signaling pathway in BV-2 microglial cells. Panel A shows that BV-2 cells were treated with
resveratrol (50 mM) for the indicated times, Panel B shows that BV-2 cells were pre-treated with resveratrol (50 mM) for 1 h, then exposed to LPS
(1 mg/ml) for the indicated times and Panels C and D shows that BV-2 cells were pre-treated with resveratrol (25, 50, and 100 mM) for 1 h, then
exposed to LPS (1 mg/ml) for 40 min. Various treated BV-2 cell lysates (50 mg protein) were prepared and subjected to Western blot analysis by using
antibodies specific for PTEN and phospho-PTEN, Akt and phospho-Akt, mTOR and phospho-mTOR as described in the methods. The relative protein
levels were quantified by scanning densitometry and normalized to total Akt. The values shown are mean 6 SEM of data from three independent
experiments.
#Significant compared with control alone, p,0.05. *Significant compared with LPS alone, p,0.05.
nSignificant compared with
resveratrol+LPS, p,0.05.
doi:10.1371/journal.pone.0032195.g003
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Over-activation of microglia contributes to neurodegenerative
processes through the production of various neurotoxic factors
including free radicals and proinflammatory cytokines [29].
Therefore, the inhibition of microglial activation could reduce
neuronal cell death. In fact, a number of anti-inflammatory agents,
which inhibit microglial activation or production of proinflamma-
tory mediators under the central nervous system disease
conditions, attenuate neuronal degeneration [30]. The present
study was undertaken to examine the pharmacological and
biological effects of resveratrol on the production of inflammatory
mediators in murine BV-2 microglia stimulated with LPS. To
further understand the molecular mechanism of resveratrol
activity in microglia, we investigated the effects of resveratrol on
the mRNA and protein expression levels of iNOS, COX-2 and
cytokines (TNF-a, IL-1b), the activation of transcription factor
NF-kB and CREB, the activation of the MAPKs family, and if
Figure 4. mTOR is required for resveratrol-inhibited expression of NO (A) and PGE2 (B) induced by LPS in BV-2 cells. Approximately
1610
6 cells/ml were seeded in six-well plates and incubated until 80% confluency. Cells were pre-treated with resveratrol (25, 50, and 100 mM) for 1 h
in the absence or presence of rapamycin (10 nM), then exposed to LPS (1 mg/ml) for 8 h. The values shown are mean 6 SEM of data from three
independent experiments.
#Significant compared with control alone, p,0.05.
*Significant compared with LPS alone, p,0.05.
nSignificant compared
with resveratrol+LPS, p,0.05.
doi:10.1371/journal.pone.0032195.g004
Figure 5. mTOR is required for resveratrol-inhibited expression of iNOS protein and mRNA induced by LPS in BV-2 cells. Panel A
shows the immunofluorenscence images for protein expression of iNOS and Panel B shows the corresponding mRNA data. The relative mRNA level
was quantified by scanning densitometry and normalized to b-actin mRNA. Note the up-regulated protein and mRNA expression of iNOS by LPS is
suppressed by different concentrations of resveratrol; however, in cells pretreated with mTOR inhibitor rapamycin, the suppressive effect of
resveratrol is abrogated. The values shown are mean 6 SEM of data from three independent experiments.
#Significant compared with control alone,
p,0.05.
*Significant compared with LPS alone, p,0.05.
nSignificant compared with resveratrol+LPS, p,0.05.
doi:10.1371/journal.pone.0032195.g005
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shows the immunofluorenscence images for protein expression of COX-2 and Panel B shows the corresponding mRNA data. The relative mRNA level
was quantified by scanning densitometry and normalized to b-actin mRNA. Note the up-regulated protein and mRNA expression of COX-2 by LPS is
suppressed by different concentrations of resveratrol; however, in cells pretreated with mTOR inhibitor rapamycin, the suppressive effect of
resveratrol is abrogated. The values shown are mean 6 SEM of data from three independent experiments.
#Significant compared with control alone,
p,0.05.
*Significant compared with LPS alone, p,0.05.
nSignificant compared with resveratrol+LPS, p,0.05.
doi:10.1371/journal.pone.0032195.g006
Figure 7. mTOR is involved in resveratrol-attenuated the production of the proinflammatory cytokine TNF-a at the transcriptional
and translational levels in BV-2 cells. Panel A shows the immunofluorenscence images for protein expression of TNF-a and Panel B shows the
corresponding mRNA data. The relative mRNA level was quantified by scanning densitometry and normalized to b-actin mRNA. Note the up-regulated
protein and mRNA expression of TNF-a by LPS is suppressed by different concentrations of resveratrol; however, in cells pretreated with mTOR inhibitor
rapamycin, the suppressive effect of resveratrol is abrogated. The values shown are mean 6 SEM of data from three independent experiments.
#Significant compared with control alone, p,0.05.
*Significant compared with LPS alone, p,0.05.
nSignificant compared with resveratrol+LPS, p,0.05.
doi:10.1371/journal.pone.0032195.g007
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and translational levels in BV-2 cells. Panel A shows the immunofluorenscence images for protein expression of IL-1b and Panel B shows the
corresponding mRNA data. The relative mRNA level was quantified by scanning densitometry and normalized to b-actin mRNA. Note the up-regulated
protein and mRNA expression of IL-1b by LPS is suppressed by different concentrations of resveratrol; however, in cells pretreated with mTOR inhibitor
rapamycin, the suppressive effect of resveratrol is abrogated. The values shown are mean 6 SEM of data from three independent experiments.
#Significant compared with control alone, p,0.05.
*Significant compared with LPS alone, p,0.05.
nSignificant compared with resveratrol+LPS, p,0.05.
doi:10.1371/journal.pone.0032195.g008
Figure 9. mTOR is required for resveratrol-inhibited expression of NF-kB/RelA protein and mRNA induced by LPS in BV-2 cells. Panel
A shows the immunofluorenscence images for protein expression of NF-kB/RelA and Panel B shows the corresponding mRNA data. The relative
mRNA level was quantified by scanning densitometry and normalized to b-actin mRNA. Note the up-regulated protein and mRNA expression of NF-
kB/RelA by LPS is suppressed by different concentrations of resveratrol; however, in cells pretreated with mTOR inhibitor rapamycin, the suppressive
effect of resveratrol is abrogated. The values shown are mean 6 SEM of data from three independent experiments.
#Significant compared with
control alone, p,0.05.
*Significant compared with LPS alone, p,0.05.
nSignificant compared with resveratrol+LPS, p,0.05.
doi:10.1371/journal.pone.0032195.g009
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activation by LPS. Approximately 1610
6 cells/ml were seeded in six-well plates and incubated until 80% confluency. Cells were pre-treated with
resveratrol (25, 50, and 100 mM) for 1 h in the absence or presence of rapamycin (10 nM), then exposed to LPS (1 mg/ml) for 30 min. Cell lysates
(50 mg protein) were prepared and subjected to Western blot analysis by using antibodies specific for phosphorylated forms of IkB-a, CREB, ERK1/2,
JNK and p38 MAPK (shown as phospho-IkB-a, etc.) as described in the methods. Equivalent loading of cell lysates was determined by reprobing the
blots with anti-b-actin, total ERK1/2, JNK or p38 MAPK antibodies. The relative protein levels were quantified by scanning densitometry and
normalized to b-actin, total ERK1/2, JNK or p38 MAPK. The values shown are mean 6 SEM of data from three independent experiments.
#Significant
compared with control alone, p,0.05.
*Significant compared with LPS alone, p,0.05.
nSignificant compared with resveratrol+LPS, p,0.05.
doi:10.1371/journal.pone.0032195.g010
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on activated BV-2 cells. The results of this study indicated that
resveratrol activated the mTOR signaling pathway and induced
mTOR phosphorylation in a time-dependent manner in BV-2
cells. Similar to resveratrol, LPS also induced slightly mTOR
phosphorylation in BV-2 cells. However, the levels of phospho-
mTOR significantly increased 40 min after the addition of LPS.
Thus, it appears that the delay in mTOR activation initially allows
LPS to activate MAPKs and induce an acute inflammatory
response. In contrast, when the cells were treated with resveratrol
before LPS stimulation, mTOR phosphorylation was elevated
initially and further increased during LPS exposure. Hence, the
proinflammatory response to LPS was suppressed by resveratrol
from the beginning, resulting in inhibition of LPS-induced
MAPKs activity and activation of transcription factor NF-kB
and CREB. PTEN is originally identified as tumor suppressor
gene mutated in a large percentage of human cancers [31]. It is
considered to be a key negative regulator of the Akt/mTOR
signaling, which is well known as a prosurvival pathway,
suggesting perspective molecular target for anti-cancer research
[32]. Moreover, several reports have suggested anti-inflammatory
activity of PTEN [33,34]. Here we further identified that
resveratrol inactivates PTEN protein by its phosphorylation in
LPS-stimulated BV-2 cells. Moreover, the presence of resveratrol
significantly increased phosphorylation of Akt in LPS-stimulated
BV-2 cells. Thus, we suggest that the modulatory effect of
resveratrol on PTEN/Akt/mTOR signaling is critical for its
inhibition of proinflammatory mediators and cytokines expression
in LPS-activated BV-2 cells.
COX-1 is constitutively expressed in most tissues, while COX-2
is induced by an array of stimuli including cytokines, LPS, and
growth factor in microglia and astrocytes [7]. COX-2 is the key
enzyme in the formation of PGE2 which appear to be an
important source of PGE2 during inflammatory conditions [35].
Microglial cells in the healthy brain do not express iNOS, but they
become activated to produce iNOS and to release a large amount
of NO following ischemic, traumatic, neurotoxic or inflammatory
damage [36]. Therefore, any substance that can attenuate
expression of iNOS and COX-2 could be beneficial for delaying
the progression of neurological disorders. In the present study,
resveratrol (25, 50, and 100 mM) significantly inhibited the
production of NO, PGE2, iNOS and COX-2 in a dose-dependent
manner in LPS-stimulated BV-2 microglial cells, suggesting
possible beneficial effects of resveratrol by attenuation of activation
of microglial cells and subsequent inflammatory neurotoxins.
More importantly, we have shown that pretreatment of BV-2 cells
with rapamycin (10 nM), a mTOR inhibitor, effectively reversed
the protective effects of resveratrol as evidenced by the reduced
expression levels of NO, PGE2, iNOS and COX-2 that were
comparable to that induced by LPS alone. These results suggest
that mTOR plays an important role in the inhibition of NO,
PGE2, iNOS and COX-2 following resveratrol-protection against
LPS-induced microglial activation.
TNF-a and IL-1b are two main proinflammatory cytokines that
are produced by activated microglia during CNS inflammation. In
the CNS, a number of stimuli, such as LPS, amyloid-b and
traumatic brain injury have been shown to abundantly produce
TNF-a and IL-1b [37,38]. Overproduction of proinflammatory
cytokines from activated microglial cells has a detrimental effect on
neuronal cells. This study investigated whether resveratrol inhibits
LPS-induced production of proinflammatory cytokines in BV-2
cells. Resveratrol inhibited LPS-induced production of TNF-a and
IL-1b in a dose-dependent manner. Meanwhile, Pre-treatment
with resveratrol significantly inhibited TNF-a mRNA levels, and
resveratrol notablely inhibited dose-dependently IL-1b mRNA
levels, compared with LPS-treated control. Furthermore, we have
shown that pretreatment of cells with rapamycin followed by
LPS+resveratrol, TNF-a and IL-1b protein and mRNA expres-
sion levels were markedly increased compared with that of the cells
treated with LPS+resveratrol. The findings support that mTOR
participates in resveratrol-inhibited expression of proinflammatory
cytokines.
The transcriptional regulation of NO, PGE2, iNOS, COX-2
and inflammatory cytokines, such as TNF-a and IL-1b, is a tightly
controlled event. A variety of transcription factors, including NF-
kB and CREB, is known to be involved in the transcriptional
regulation of these inflammatory mediators [39]. In un-stimulated
cells, NF-kB is retained in the cytoplasm by binding to IkB-a. The
processes of NF-kB activation include degradation through
phosphorylation and a subsequent nuclear translocation of the
RelA subunit of NF-kB. The molecular mechanisms underlying
anti-inflammatory effect of resveratrol, which showed the most
potent anti-inflammatory activity, were further studied. The
present results have shown that NF-kB/RelA level, markedly
increased by LPS stimulation in BV-2 cells, was effectively
reversed by resveratrol treatment in a mTOR-dependent manner.
Concomitantly, pre-incubation of LPS stimulated cells with
rapamycin reversed the resveratrol-induced phosphorylation of
IkB and CREB. These results indicated that the inhibition of
resveratrol on the expression of NO, PGE2, iNOS, COX-2 and
proinflammatory cytokines is partially through the suppression of
NF-kB/RelA expression, the phosphorylation of IkB-a and CREB
in a mTOR-dependent manner in LPS-stimulated BV-2 cells.
MAPKs family has been shown to play important roles in LPS-
induced iNOS, COX-2, and proinflamatory cytokines expression
in many types of cells [40,41,42]. It also has been reported that
LPS-induced proinflammatory cytokines expression is mediated
by MAPKs signal transduction pathway in BV-2 cells [43].
Therefore, we investigate the effect of resveratrol on activation
(phosphorylation) of three MAPKs induced by LPS in BV-2 cells.
The results of this study indicate that resveratrol inhibits LPS-
increased activation of MAPKs, including ERK1/2, JNK, and
p38 MAPK, within 30 min after stimulation, whereas resveratrol
decreased LPS-induced activation of MAPKs, which was accom-
panied by alterations in NO, PGE2, iNOS, COX-2, and pro-
inflammatory cytokines. This result is inconsistent with a recent
study [27]. The discrepancy may be due to differences in cell
origin and experimental conditions (Our data indicate that
resveratrol-inhibited activation of MAPKs occurs at higher
concentrations). Additionally, rapamycin partly reversed the effect
of resveratrol-inhibited phosphorylation of ERK1/2, JNK and
p38 MAPK.
In conclusion, this investigation demonstrates that resveratrol
significantly attenuates overactivation of microglial cells by re-
pressing expression levels of neurotoxic proinflammatory mediators
and cytokines via activation of mTOR signaling pathway. These
results suggest the potential of resveratrol as an anti-inflammatory
drug candidate.
Methods
Cells and treatments
The mouse microglial cell line BV-2 was developed in the
laboratory of Dr Blasi at the University of Perugia and was a
generous gift of Dr Cheng-gang Zou (School of Life Science,
Yunnan University, Kunming, China). Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco/BRL,
Gaithersburg, MD, USA) containing 2% fetal bovine serum
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and 100 mg/ml streptomycin; Sigma, St. Louis, MO, USA) at a
density not exceeding 5610
5 cells/ml and maintained at 37uCi na
humidified incubator with 5% CO2. To harvest BV-2 cells, cells
were trypsinized (0.25% trypsin/EDTA in phosphate-buffered
saline (PBS); Sigma, St. Louis, MO, USA), then centrifuged (400 g
for 10 min) and resuspended in serum-free DMEM. Cells were
counted with a hemocytometer and trypan blue staining (0.4%
trypan blue in PBS; Sigma) showed more than 98% of the cells
retained viability. Cells (approximately 1610
6 cells/ml) were
seeded in six-well plates before being subjected to treatments.
Resveratrol (Purity.99%; Kunming Pharmaceutical Corporation,
Kunming, China) at 25, 50, and 100 mM was added 1 h before
LPS (1 mg/ml) (from Escherichia coli, Sigma) stimulation. This time
point was chosen to minimize the possibility of any direct
interactions between resveratrol and LPS. Cell incubations ranged
from 20 min–18 h, as indicated in the text.
Cell cytotoxicity test
The cells were seeded in a 24-well dish (1610
6 cells/ml) for 24 h
before being exposed to resveratrol (25, 50, and 100 mM),
resveratrol with LPS (1 mg/ml), resveratrol with rapamycin
(10 nM), or resveratrol with LPS+rapamycin for 18 h. MTT
solution (0.5 mg/ml) was then added to each well and the cells
were incubated for 2 h at 37uC and in 5% CO2. Subsequently, the
supernatant was removed and the formation of farmazan was
solubilized with dimethyl sulfoxide (DMSO) and measured at
540 nm with a microplate reader.
Assay of NO production
Various treated BV-2 cells were plated in 48-well plates at a
density of 1610
6 cells/ml for 8 h. NO production was monitored
by measuring the nitrite content in culture medium as previously
described [7]. The isolated supernatant was mixed with an equal
volume of Griess reagent (0.1%N-1-naphthylethylenediamine
dihydrochloride and 1% sulphanilamide in 5% phosphoric acid)
and incubated at room temperature for 10 min. Absorbance was
measured at 550 nm in a microplate reader. Sodium nitrite was
used as a standard.
Determination of PGE2 production
Varioustreated BV-2 cellswere treated for8 h to permitcytokine
production. The PGE2 concentration in the culture medium was
quantified using a competitive enzyme immunoassay kit (R&D
Systems Inc., MN, USA) in accordance with the manufacturer’s
instructions. The production of PGE2 was measured relative to that
observed after control treatment.
Double-immunofluorescence labeling assay
BV-2 cells derived from various treatments were fixed with 4%
paraformaldehyde in 0.1 M phosphate buffer (PB) for 15 min.
After rinsing with PBS, the coverslips with adherent cells were
used for double immunofluorescence labeling. BV-2 cells were
incubated with DAPI (dilution 1:50,000; Sigma) plus goat anti-
mouse iNOS (dilution 1:500; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), goat anti-mouse COX-2 (dilution 1:500; Santa
Cruz Biotechnology), goat anti-rabbit TNF-a polyclonal antibody
(dilution 1:500; Chemicon, Temecula, CA,USA), goat anti-rabbit
IL-1b (dilution 1:500; Chemicon), or goat anti-rabbit NF-kB/
RelA (dilution 1:500; Santa Cruz Biotechnology). Subsequently,
the cells were incubated with TRITC-conjugated secondary
antibody (Santa Cruz Biotechnology) for 1 h at room temperature.
For negative controls, a set of culture slides was incubated under
similar conditions without the primary antibodies. All images were
captured with a fluorescence microscope (80i; Nikon, Tokyo,
Japan). The results are representative of three independent
experiments.
Reverse transcription-polymerase chain reaction (RT-PCR)
analysis
Afterincubation,media wasremoved andBV-2 cellswerewashed
with phosphate-buffered saline (PBS) twice. Total RNA was
prepared from BV-2 cells by using the TrizolH reagent (Invitrogen
Corporation, Carlsbad, CA, USA) according to the manufacturer’s
protocol. cDNAwas prepared using reverse transcriptase originating
from the Superscript
TM-III kit (Invitrogen) with 2.5 mg total RNA
and oligo dT. The sequences of PCR primers were as follows: iNOS,
sense: 59- CTGCAGCA CTTGGATCAGGAACCTG -39, anti-
sense: 59- GGGAGTAGCCTGTGTGCACCTGGAA -39;C O X -
2, sense: 59-TTGAAGACCAGGAGTACAGC-39, antisense: 59-G
GTACAGTTCCATGACA TCG-39; TNF-a,s e n s e :5 9-CGTCAG
CCGATTTGCTATCT-39,a n t i s e n s e :5 9-CGGACTCCGCAAA G
TCTAAG-39;I L - 1 b,s e n s e :5 9-GCCCATCCTCTGTGACTCAT-
39,a n t i s e n s e :5 9-AGGCCACAGG TATTTTGTCG-39;N F - kB/
RelA, sense: 59-GCGTACACATTCTGGGGAGT-39, antisense:
59-CCGAAGCAGGAGCTATCAAC-39; b-actin, sense: 59-AGC-
CATGTACGTAGCCATCC-39,a n t i s e n s e :5 9-GCTGTGGTGGT
GAAGCTGTA-39. PCR amplification of the resulting cDNA
template was conducted by using the following conditions for 45
(TNF-a, IL-1b,N F - kB/RelA and b-actin), 36 (COX-2) or 27
(iNOS) cycles. After an initial denaturation step at 95uCf o r1 5m i n ,
temperature cycling was initiated. Each cycle consisted of denatur-
ation at 94uC for 15 sec, annealing at 60uC for 25 sec, and
elongation at 72uCf o r2 0s e c( T N F - a, IL-1b,N F - kB/RelA and b-
actin). For COX-2, after an initial denaturation step at 95uCf o r
5 min, temperature cycling was initiated. Each cycle consisted of
denaturation at 94uC for 30 sec, annealing at 57uC for 45 sec, and
elongation at 72uC for 30 sec. For iNOS, after an initial
denaturation step at 95uC for 5 min, temperature cycling was
initiated. Each cycle consisted of denaturation at 94uC for 45 sec,
annealing at 60uC for 45 sec, and elongation at 70uCf o r1m i n .
PCR products were analyzed on 1% agarose gels and stained with
1 mg/ml ethidium bromide. Images were captured with a Gel Doc
2000 image analyzer (Bio-Rad, Richmond, CA, USA). The results
are representative of three independent experiments.
Western blot analysis
BV-2 cells were incubated in a medium without 2% FBS for at
least 4 h before treatments. They were harvested with ice-cold
PBS and centrifuged at 16 0006 g for 5 min at 4uC. Stimulated
cells were lysed in ice-cold lysis buffer [62.5 mM Tris–HCl,
pH 6.8, 25% glycerol, 2% sodium dodecyl sulphate (SDS), 0.01%
bromphenol blue and 5% b-mercaptoethanol]. Cell lysates were
centrifuged at 16 0006g for 5 min at 4uC, then the supernatants
were collected. Protein content was determined by using the BCA
protein assay (Pierce, Rockford, IL, USA). Equal amounts of total
cellular protein (50 mg) were loaded per lane onto 10% SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
onto immunoblot polyvinylidene difluoride membranes (Chemi-
con). The membranes were blocked with 5% non-fat milk in Tris-
buffered saline containing 0.1% Tween 20 (TBS-T) for 2 h and
incubated separately with goat anti-rabbit antibodies for PTEN
and phospho-PTEN, Akt and phospho-Akt, mTOR and phospho-
mTOR, ERK1/2 and phospho-ERK1/2, JNK and phospho-
JNK, p38 MAPK and phospho-p38 MAPK, phospho-IkB-a,
phospho-CREB and b-actin antibodies (1:1000 dilution; Cell
Signaling Technology, Danvers, MA, USA) that recognize
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membranes were then washed three times for 15 min with TBS-
T, and incubated with a 1:2000 dilution of horseradish peroxidase-
coupled secondary antibodies (Santa Cruz Biotechnology) for 2 h
at room temperature. Blots were again washed three times for
5 min each in TBS-T and developed by the ECLH detection
system (Santa Cruz Biotechnology). Membranes were exposed to
Fuji Medical X-Ray Film (Fuji Photo Film Co., Ltd, Karagawa,
Japan).
Statistical analysis
Statistical analysis of the data was carried out by one way
analysis of variance (ANOVA) followed by Scheffe’s post hoc test,
using SPSS (SPSS Inc., Chicago, IL, USA). Summary data are
shown as mean 6 SEM (standard error of mean) obtained from
three independent experiments. Values of p,0.05 were considered
significant. (
#p,0.05, *p,0.05,
np,0.05).
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